How Gilead Sciences Makes its Money: Revenue Breakdown
A breakdown of Gilead Sciences (GILD) financials. See how Gilead Sciences makes money from Biktarvy (HIV), Other HIV Products, Veklury (COVID-19), and more using their 2024 annual report.
How Does Gilead Sciences Make its Money?
Gilead Sciences is a biopharmaceutical company that dominates the global HIV treatment market and is rapidly expanding into oncology. The company’s Biktarvy has become the most prescribed HIV treatment in the world, taken as a single daily pill by millions of patients. Gilead also developed Veklury (remdesivir), which became the standard antiviral treatment for hospitalized COVID-19 patients.
Gilead has been transforming from a virology-focused company into a broader biopharma platform through strategic acquisitions. The $11.9B purchase of Kite Pharma (2017) brought CAR-T cell therapy for blood cancers, and the $21B acquisition of Immunomedics (2020) added Trodelvy, an antibody-drug conjugate for breast and bladder cancer. These moves reflect Gilead’s strategy to build a cancer franchise that can drive growth as its mature HIV products plateau.
Gilead Sciences (GILD) Business Model
Gilead Sciences operates in the biotechnology sector, generating revenue from patented prescription drugs across virology (HIV, hepatitis, COVID-19), oncology, and inflammation. The company invests ~$5.5B annually in R&D and commercializes drugs globally through its own sales force. This breakdown uses data from Gilead Sciences’ 2024 fiscal year filings with the SEC.
Gilead’s HIV franchise is unique in pharma because it generates massive, highly predictable recurring revenue. HIV patients take antiretroviral therapy for life, creating a durable and growing revenue base as Gilead expands into newly diagnosed patients and switches patients from older regimens to Biktarvy.
Gilead Sciences Competitors
Gilead Sciences’s key competitors and comparable public companies in the biotechnology sector include Amgen, Eli Lilly, Pfizer, and Moderna. Each of these companies competes for market share, investor attention, and revenue in overlapping segments. See how Gilead Sciences stacks up by comparing their revenue breakdown, margins, and growth metrics.
Revenue Breakdown
| Segment | 2024 | 2023 | YoY Growth |
|---|---|---|---|
| Biktarvy (HIV) | $13,500M | $12,100M | +11.6% |
| Other HIV Products | $3,700M | $4,100M | -9.8% |
| Oncology (Trodelvy, Yescarta, Tecartus) | $3,200M | $2,600M | +23.1% |
| Liver Disease (Vemlidy, etc.) | $2,800M | $2,700M | +3.7% |
| Veklury (COVID-19) | $1,400M | $1,900M | -26.3% |
| Other Products | $3,200M | $2,700M | +18.5% |
| Total Revenue | $28,300M | $27,100M | +4.4% |
Biktarvy — 48% of Revenue
Biktarvy ($13.5B) is a single-tablet regimen combining three antiretroviral drugs for HIV treatment. It’s the #1 prescribed HIV drug globally, with dominant market share in both treatment-naive (newly diagnosed) and switch patients. Revenue grew 11.6%, driven by continued market share gains and pricing. Biktarvy’s patent protection extends into the early 2030s, providing years of runway.
The HIV treatment market has unique characteristics: once a patient is stabilized on a regimen, physicians are reluctant to switch unless there’s a compelling clinical reason. This creates exceptionally high brand loyalty and low churn, making Biktarvy’s revenue base one of the most predictable in pharma.
Oncology — 11% of Revenue
Gilead’s fastest-growing segment ($3.2B, +23.1%) includes Trodelvy (antibody-drug conjugate for breast and bladder cancer), Yescarta (CAR-T cell therapy for lymphoma), and Tecartus (CAR-T for mantle cell lymphoma). Trodelvy is expanding into new indications and geographies, while Yescarta is being tested in earlier-line settings where it could significantly expand its addressable market.
CAR-T therapy is a transformative but complex treatment — a patient’s own immune cells are extracted, genetically engineered to fight cancer, and re-infused. Manufacturing challenges and high costs (~$400K per treatment) limit volume but drive very high per-patient revenue.
Liver Disease — 10% of Revenue
Vemlidy and other liver disease drugs ($2.8B) treat chronic hepatitis B. This is a mature but stable franchise that provides reliable cash flow. The hepatitis C cure franchise (Sovaldi, Harvoni) that originally made Gilead famous has largely wound down as the treatable patient pool shrinks.
Veklury — 5% of Revenue
Veklury ($1.4B) continues to decline as COVID-19 hospitalizations decrease. Revenue dropped 26.3% and is expected to settle into a modest steady state as COVID becomes endemic, with Veklury used for severe hospitalized cases.
Gilead Sciences (GILD) Income Statement
| Metric | 2024 | 2023 |
|---|---|---|
| Total Revenue | $28,300M | $27,100M |
| Gross Profit | $20,300M | $19,500M |
| Operating Income | $8,900M | $7,000M |
| Net Income | $6,400M | $5,500M |
Financial data sourced from Gilead Sciences SEC Filings.
Gilead Sciences (GILD) Key Financial Metrics
- Gross Margin: 71.7% — Strong, reflecting the high pricing power of patented HIV and oncology drugs. Biktarvy alone likely carries 90%+ gross margins.
- Operating Margin: 31.4% — Excellent, improved from 25.8% in 2023 as revenue growth outpaced operating expense growth. Gilead’s operating leverage is increasing as oncology products scale.
- Revenue Growth: 4.4% — Modest growth as Biktarvy and oncology expansion offset Veklury and older HIV product declines.
Is Gilead Profitable?
Yes, Gilead is highly profitable, reporting $6.4B in net income on $28.3B in revenue. The company generates approximately $8B in annual free cash flow, which funds its $4B+ annual dividend, active share buyback program, and M&A pipeline. Gilead’s profitability has been consistent for over a decade, supported by the HIV franchise’s durable revenue streams and high margins.
Gilead Sciences (GILD): What to Watch
- Lenacapavir (Sunlenca) for HIV prevention — Gilead’s long-acting injectable, currently approved for treatment, is in late-stage trials for PrEP (pre-exposure prophylaxis). If approved, lenacapavir could become a twice-yearly injection to prevent HIV, potentially expanding Gilead’s addressable market by billions.
- Oncology portfolio ramp — Trodelvy and Yescarta need to collectively reach $8-10B in revenue to make oncology a meaningful growth driver. Expansion into earlier treatment lines and new tumor types is critical.
- Biktarvy lifecycle extension — As Biktarvy’s patent window closes in the early 2030s, Gilead is developing next-generation long-acting HIV regimens (including lenacapavir combinations) to transition patients to new franchise products.
- Inflammation pipeline — Gilead has multiple clinical-stage assets in inflammation (including STING agonists). Success here would add a third therapeutic pillar beyond virology and oncology.
- M&A strategy — With strong free cash flow and a relatively focused portfolio, Gilead has significant capacity for acquisitions. The quality of future deals will determine whether the company can sustain growth through the 2030s.
Gilead Sciences (GILD) Financial Summary
Gilead Sciences (GILD) is a biotechnology company that generated $28.3B in total revenue in fiscal year 2024, growing 4.4% year-over-year. Biktarvy, the world’s #1 HIV treatment, contributed $13.5B while the oncology portfolio grew 23.1%. The company earned $6.4B in net income with industry-leading 31.4% operating margins. For a deeper look at Gilead Sciences’ revenue breakdown, business segments, and financial performance, review the detailed analysis above.
Weekly Company Breakdowns — Visualized
See how top companies actually make money. Visual revenue breakdowns delivered free every week.